VERV Company Profile and Key Details
Verve Therapeutics, Inc.
VERV Stock Price Chart
Stock Price Today
Verve Therapeutics, Inc. (VERV) stock surged +18.11%, trading at $7.76 on NASDAQ, up from the previous close of $6.57. The stock opened at $6.62, fluctuating between $6.62 and $7.79 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 255 |
| Beta | 1.76 |
| Sales or Revenue | $11.76M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Verve Therapeutics, Inc. (NASDAQ: VERV) stock price is $7.76 in the last trading session. During the trading session, VERV stock reached the peak price of $7.79 while $6.62 was the lowest point it dropped to. The percentage change in VERV stock occurred in the recent session was 18.11% while the dollar amount for the price change in VERV stock was $1.19.
The NASDAQ listed VERV is part of Biotechnology industry that operates in the broader Healthcare sector. Verve Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Barry S. Ticho FACC, M.D., Ph.D.
Chief Medical Officer
Ms. Allison Dorval
Chief Financial Officer & Principal Accounting Officer
Mr. Jason Politi
Senior Vice President of Technical Operations
Dr. Anthony Philippakis M.D., Ph.D.
Co-Founder & Scientific Advisory Board Member
Mr. Issi Rozen M.B.A.
Co-Founder & Strategic Advisor
Ms. Margaret Beaudoin
Vice President of Fin.
Dr. Burt A. Adelman M.D.
Co-Founder & Independent Chairman
Dr. Sekar Kathiresan M.D.
Co-Founder, Chief Executive Officer & Director
Mr. Andrew D. Ashe J.D.
Pres, Chief Operating Officer & Gen. Counsel
Dr. Andrew Bellinger M.D., Ph.D.
Chief Scientific Officer & Chief Medical Officer
Dr. Kiran Musunuru M.D., M.P.H., Ph.D.
Co-Founder & Senior Scientific Advisor
VERV's closing price is 52.61% higher than its 52-week low of $4.31 where as its distance from 52-week high of $19.34 is -66.03%.
Number of VERV employees currently stands at 255.
Official Website of VERV is: https://www.vervetx.com
VERV could be contacted at phone 617 603 0070 and can also be accessed through its website. VERV operates from 500 Technology Square, Cambridge, MA 02139, United States.
VERV stock volume for the day was 2.54M shares. The average number of VERV shares traded daily for last 3 months was 1.57M.
The market value of VERV currently stands at $656.99M with its latest stock price at $7.76 and 84.66M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com